HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictors of poor response after primary immunization of hepatitis B vaccines for infants and antibody seroprotection of booster in a metropolis of China.

Abstract
To evaluate proportion and predictors of poor response in infants and appraise booster seroprotection, we surveyed 2047 infants in Shanghai and detected antibody to hepatitis B (HB) surface antigen (anti-HBs). Poor responders were randomized into 2 groups, given booster with 5 µg and 10 µg hepatitis B vaccine (HepB), respectively. Proportion of infants with titer <10 mIU/mL and 10 to 99 mIU/mL was 1.86% and 15.14%, respectively. Multivariate logistic regression suggested infants of male, aged 13 to 18 months, premature, administered with 5 µg HepB or mother positive for HB surface antigen (HBsAg) and HBe antigen (HBeAg) would more likely develop worse response. Difference of geometric mean concentration between the first and full booster was not statistically significant both for 5 µg and for 10 µg HepB groups. The seroprotective rate were higher for infants with 10 µg HepB than those with 5 µg HepB (P > .05). Therefore, it is concluded that booster for poor vaccinees with 10 µg HepB could achieve satisfactory seroprotection.
AuthorsJian Li, Jiayu Hu, Xiaofeng Liang, Fuzhen Wang, Yanting Li, Zheng-an Yuan
JournalAsia-Pacific journal of public health (Asia Pac J Public Health) Vol. 27 Issue 2 Pg. NP1457-66 (Mar 2015) ISSN: 1941-2479 [Electronic] China
PMID24097922 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013 APJPH.
Chemical References
  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
Topics
  • China
  • Hepatitis B Antibodies (blood)
  • Hepatitis B Surface Antigens (blood)
  • Hepatitis B Vaccines (immunology)
  • Humans
  • Immunization, Secondary
  • Infant
  • Logistic Models
  • Male
  • Surveys and Questionnaires

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: